Nucor earnings beat by $0.08, revenue fell short of estimates
RICHMOND, Va. - Indivior PLC (NASDAQ:INDV) (LSE:INDV), a pharmaceutical company with a market capitalization of $1.74 billion and impressive gross margins of 82%, has appointed Tony Kingsley to its Board of Directors as an Independent Non-Executive Director, effective July 1, 2025, according to a company press release. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimates.
Kingsley, who currently serves as CEO and Director of biotechnology company Stablix, Inc., was appointed with support from affiliates of Oaktree Capital Management, L.P., under Indivior’s relationship agreement with the investment firm.
David Wheadon, Chair of Indivior’s Board, said Kingsley’s "significant commercial and clinical development experience will be invaluable" to the company as it works to develop its SUBLOCADE product.
Kingsley brings extensive pharmaceutical industry experience to the role. Before joining Stablix, he served as President and CEO of Scholar Rock and led TARIS Bio through its acquisition by Janssen Pharmaceuticals in 2019. His career also includes senior leadership positions at The Medicines Company and Biogen, where he oversaw multiple therapy launches in neurology and hemophilia.
Earlier in his career, Kingsley held senior management roles in medical devices and diagnostics and worked as a partner at McKinsey & Company. He holds a magna cum laude degree from Dartmouth College and an MBA from Harvard Business School.
Indivior, headquartered in Richmond, Virginia, focuses on developing treatments for opioid use disorder. The company employs over 1,000 people globally and markets its products in more than 30 countries. Recent financial data shows annual revenue of $1.17 billion, with analysts expecting net income growth in the coming year. The company’s next earnings report is scheduled for July 24, 2025.
In other recent news, Indivior PLC has announced the appointment of Patrick Barry as its new Chief Commercial Officer. Barry brings over 30 years of experience in the pharmaceutical sector and is expected to drive the company’s commercial growth strategy, particularly focusing on SUBLOCADE®, a treatment for opioid use disorder. Concurrently, Indivior has undergone significant leadership changes, with Joe Ciaffoni stepping in as the new CEO following the departure of Mark Crossley. These changes were approved during the company’s Annual General Meeting, where shareholders also agreed on amendments to the company’s articles of association, reflecting its transition to the Nasdaq Stock Market.
Additionally, Indivior has been actively engaging with shareholders regarding its remuneration policy. The company has sent letters to major institutional shareholders to explain the policy’s details and rationale ahead of the next AGM. The AGM Notice and related shareholder communications have been made available on Indivior’s website and included in a recent SEC filing. These developments underscore Indivior’s strategic direction and commitment to addressing challenges in addiction treatment under its new leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.